Fujifilm

Fujifilm and VolitionRx Collaborate on Groundbreaking Veterinary Cancer Test

Exciting partnership alert! Fujifilm and VolitionRx team up to revolutionize cancer testing in the veterinary world.

In a groundbreaking collaboration, VolitionRx Limited and Fujifilm Vet Systems have joined forces to launch the Nu.Q® Vet Cancer Test. This innovative test, combining the expertise of a multi-national epigenetics company and Fujifilm's cutting-edge technology, aims to revolutionize cancer diagnosis in veterinary medicine. The Nu.Q® Vet Cancer Test is set to provide accurate and timely detection of cancer in pets, offering new hope to animal lovers worldwide.

Adding to the excitement, Fujifilm has recently received 510(k) clearance for CAD EYE®, an AI-powered technology that enables real-time detection of colonic mucosal lesions during colonoscopy procedures. CAD EYE® supports endoscopists by enhancing their ability to identify polyps and adenomas, showcasing Fujifilm's commitment to advancing medical imaging technology.

These advancements mark a significant milestone in the field of veterinary medicine, paving the way for improved cancer diagnostics and treatment for pets. The collaboration between Fujifilm and VolitionRx represents a synergy of innovation and expertise, promising a brighter future for our furry friends.

In conclusion, the Nu.Q® Vet Cancer Test and CAD EYE® by Fujifilm are not just technological marvels but also symbols of hope and progress in the fight against cancer, both in animals and humans. With these cutting-edge advancements, the future of veterinary medicine looks brighter than ever before.